

(Download) New Drug Development: A Regulatory Overview (NEW DRUG DEVELOPMENT (MATHIEU))

New Drug Development: A Regulatory Overview (NEW DRUG DEVELOPMENT (MATHIEU))

Mark P. Mathieu, Anne G. Evans

*ePub | *DOC | audiobook | ebooks | Download PDF*

 Download

 Read Online

#1361839 in Books Parexel International Corporation 2005-05 Original language: English PDF # 1 11.00 x 8.50 x 1.00l, #File Name: 1882615727389 pages | File size: 29.Mb

Mark P. Mathieu, Anne G. Evans : New Drug Development: A Regulatory Overview (NEW DRUG DEVELOPMENT (MATHIEU)) before purchasing it in order to gage whether or not it would be worth my time, and all praised New Drug Development: A Regulatory Overview (NEW DRUG DEVELOPMENT (MATHIEU)):

3 of 4 people found the following review helpful. Regulatory Affairs Textbook StandardBy Catherine V. VelazquezThe book is a comprehensive collection of Regulatory Affairs information. The book lacks an index. Thankfully, the table of contents is detailed enough to find most of the information one might be looking for.2 of 5 people found the following review helpful. \$189.00????By K. ScullionI can get this through the Temple bookstore for \$175.00 brand new - and I thought that was expensive!! Unfortunately, I have the older edition and need to buy the new one. The older edition is a good book, so I imagine this one is just as informative. Gives a very good picture of drug development.

Go inside the drug development and FDA regulatory process with today's most authoritative and popular reference on the topic. In its all-new 2008 edition, New Drug Development: A Regulatory Overview addresses the most cutting-edge developments redefining how new drugs are developed and regulated today, including:* How the FDA

Amendments Act of 2007 will affect everything from drug reviews to postmarketing requirements.* How the CDER's efforts to integrate a culture of drug safety has affected the center's structure and its new drug review and approval processes.* How CDER's much-anticipated January 2008 transition to the eCTD as the only valid esubmission format will affect the FDA's drug submission and review process.* How the FDA and industry are already integrating pharmacogenomics, computer simulation, and other emerging technologies to inform key decisions.* Which drug development strategies are fulfilling their promise and offering optimal returns for industry, given the explosion of accelerated development/approval programs and pilot programs to speed the drug development and review process. Find out why New Drug Development is pharma/biotech's go-to resource for regulatory, clinical, project management, training, and other drug development disciplines navigating the FDA's drug development approval processes.

This book provides the most comprehensive and up-to-date analysis of FDA's new drug development process available today. I recommend this well-written book for professionals engaged in the drug development and review process. --
Biopharm Magazine
This book is superb! It is the single best source of information on the drug regulatory system. --
Peter Barton Hutt, Covington Burling